Trials / Completed
CompletedNCT01951755
Phase IV Study of Tarceva in Patients With Advanced Stage IIIB/ IV Non-small Cell Lung Cancer (NSCLC)
An Observational Study for Safety and Efficacy of Erlotinib Beyond 1st Line in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 150 (actual)
- Sponsor
- University of Athens · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
An open-label, non randomized clinical trial of Tarceva as single agent in progressed non-small cell lung cancer patients.
Detailed description
An observational non randomized clinical trial of Tarceva as single agent in progressed non-small cell lung cancer patients after chemotherapy.
Conditions
Timeline
- Start date
- 2012-01-01
- Primary completion
- 2014-01-01
- Completion
- 2014-01-01
- First posted
- 2013-09-27
- Last updated
- 2014-12-08
Locations
1 site across 1 country: Greece
Source: ClinicalTrials.gov record NCT01951755. Inclusion in this directory is not an endorsement.